Treatment of Malignant Peritoneal Mesothelioma (MESOTIP)

Stopped This decision was taken following the occurrence of three cases of serious and unexpected suspected adverse reactions (SUSARs), specifically febrile neutropenia, in participants assigned to the experimental arm combining PIPAC with systemic chemothe

Conditions

• Peritoneal Mesothelioma
• Peritoneal Carcinomatosis

Interventions

• PROCEDURE: PIPAC
• DRUG: Cisplatin
• DRUG: Pemetrexed

Sponsor

Institut du Cancer de Montpellier - Val d'Aurelle